Overexpression of utrophin thus has been proposed as a potential DMD therapy and has been tested preclinically and clinically (27, 28, 29, 30); it is naturally expressed in dystrophic muscle, and its overexpression can compensate for dystrophin deficiency in mice (31, 32). This evidence concerns the gene UTRN and Duchenne muscular dystrophy.